Nestlé has completed its sale of 24.8% of Alcon’s issued and outstanding capital to Novartis following the conclusion of the regulatory process.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more


The cash transaction concerns 74 million Alcon shares at US$143 per share, with an aggregate value of $10.4bn after dividend adjustment.


The sale will have no capital gains tax impact on Nestlé which retains close to 52% of Alcon’s issued and outstanding capital and continues to fully consolidate Alcon.


The proceeds of the transaction will be used to reduce debt as Nestlé pursues its on-going share buy-back programme.


As announced on 7 April, Nestlé has a put option and Novartis a call option exercisable in the period from January 2010 to July 2011 on the remaining Alcon shares owned by Nestlé.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Just Food Excellence Awards - Nominations Closed

Nominations are now closed for the Just Food Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Winning five categories in the 2025 Just Food Excellence Awards, Centric Software is setting the pace for digital transformation in food and FMCG. Explore how its integrated PLM and PXM suite delivers faster launches, smarter compliance and data-driven growth for complex, multi-channel product portfolios.

Discover the Impact